Sep 29, 2019
Aravax receives positive pre-IND feedback from FDA on PVX108 Phase 2 trial plans.
30 September 2019, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for...
top of page
Developing safe, convenient, disease-modifying treatments for food allergies.
.jpg)
News
bottom of page